액토스정®(피오글리타존 30 mg)에 대한 염산피오글리타존정의 생물학적동등성
Bioequivalence of pioglitazone tablet to Actos® tablet(Pioglitazone 30 mg)
0
조회
0
다운로드
0
인용
0
참고문헌
초록
다케다약품공업주식회사의 “액토스정<SUP>®</SUP> 30 ㎎”을 대조약으로 하고 보령제약주식회사의 “염산피오글리타존정 30 ㎎”을 시험약으로 하여, 2×2 교차시험법에 따라 지원자 28 명을 대상으로 생물학적동등성시험을 실시하였다. 이를 위하여 피오글리타존 30 mg을 각 지원자에게 경구 투여한 후, 0-36 시간동안 채혈한 혈장 시료를 확보하였다. 혈장 중 피오글리타존을 분석하기 위하여, LC-MS/MS 분석법을 확립하였으며 분석결과의 신뢰성을 높이기 위하여 분석법 검증을 수행하였다. 그 결과, 5-2000 ng/mL의 농도범위에서 우수한 직선성을 나타내었으며, 생물학적동등성시험에 이용될 수 있는 충분한 감도와 특이성, 정밀성 및 정확성을 확인하였다. 각 피험자들의 혈중 약물농도 데이터로부터 구한 혈중약물농도-시간곡선하면적(AUC<SUB>t</SUB>)과 최고혈중농도(C<SUB>max</SUB>) 등의 약물속도론적 파라미터에 대해 통계학적으로 고찰한 결과, 판정기준을 만족 시켰으며, 따라서 두 제제는 생물학적으로 동등한 것으로 평가하였다.
Abstract
The bioequivalence of two pioglitazone tablets, Actos<SUP>®</SUP> tablet (Takeda Chemical Industries, reference drug) and Pioglitazone tablet (Boryung Company, test drug) was evaluated according to the guidelines of Korea Food and Drug Administration. Twenty-eight healthy male Korean volunteers received each medicine (pioglitazone dose of 30 mg) in a 2×2 crossover study with one week washout interval. After drug administration, blood samples were collected at specific time intervals from 0-36 hours. The plasma concentrations of pioglitazone were determined by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The total chromatographic run time was 5 min and calibration curves were linear over the concentration range of 5-2000 ng/mL for pioglitazone. The method was validated for selectivity, sensitivity, linearity, accuracy and precision. The pharmacokinetic parameters were determined from the plasma concentration-time profiles of both formulations. The primary calculated pharmacokinetic parameters were compared statistically to evaluate bioequivalence between the two preparations. The 90% confidence intervals of the AUCt ratio and the C<SUB>max</SUB> ratio for Pioglitazone tablet and Actos<SUP>®</SUP> tablet were log0.9422~log1.1040 and log0.9200~log1.1556, respectively. Based on the statistical considerations, we can conclude that the test drug, Pioglitazone tablet was bioequivalent to the reference drug, Actos<SUP>®</SUP> tablet.
참고문헌 (11)
- J. Waugh, , Drugs, 66, pp.85~109 (2006)
- "Takeda Pharmaceutical Company Limited, Actos® (pioglitazone hydrochloride) Full Prescribing Information, Osaka, Japan" (2004)[URL]
- J. M. Lehmann, , J. Biol. Chem, 270, pp.12953~12956 (1995)
- J. Sakamoto, , Biochem. Biophys. Res. Commun., 278, pp.704~711 (2000)
- J. Chilcott, MSc, , Clin. Therapeut, 23, pp.1792~ (2001)
- P. Sripalakit, , J. Chromatogr. B, 843, pp.164~169 (2006)
- S. Wittayalertpanya, , J. Med. Assoc. Thailand, 89, pp.2116~2122 (2006)
- "식품의약품안전청 고시 제 2007-65호, 생물학적동등 성시험기준 (2007. 09. 20)", ~ (2007)
- Y. J. Xue, , J. Chromatogr. B, 795, pp.215~226 (2003)
- "International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures, ICH-Q2A, Geneva", ~ (1995)
- "FDA Guidelines, Bioequivalence Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs, Rockville, MD USA", ~ (1992)